The current UCSD CFAR is a component of the AID Research Institute, an Organized Research Unit in the University of California System. We propose to expand the CFAR into a regional, comprehensive AIDS Research Center, with participating members drawn from UCSD and neighboring institutions including the Salk Institute, Scripps Research Foundation, the Burnham Cancer Research Foundation, and the La Jolla Institute for Allergy and Immunology. Dr. Flossie Wong-Staal and Dr. Douglas Richman will continue to serve as the Director and Co-director of the new Center. Their cooperation and complementary areas of expertise should strengthen the interaction of basic and clinical AIDS research as well as ensuring a continuation in leadership. The central mission of the new CFAR is to develop improved vaccines and therapies for HIV infection and associated disease through: (i) Basic Research in the areas of molecular pathogenesis and immunopathogenesis of HIV infection; (ii) Utilization of insights from basic research to develop pre-clinical and clinical trials of therapies and vaccines; (iii) Further clinical research to address fundamental scientific and practical medical issues; (iv) Providing leadership and serving as a regional resource to coordinate, stimulate and cross- fertilize all of the above to foster synergism, economies of scale and novel and creative approaches. The new CFAR will have a greatly strengthened Administrative Core to effectively coordinate the diverse activities of the Center. The Developmental Core will also be expanded in accordance with the growth in participating membership from neighboring institutions. A number of new cores will be established to keep pace with current needs and research activities on HIV. The proposed cores include five basic sciences cores: Molecular Biology, Virology, Flow Cytometry, Gene Therapy and Signal Transduction/Apoptosis and four clinical cores: Clinical Data and Outcomes, Clinical Investigation, Behavioral and Health Function and Primary Isolation and Specimen Banking. In addition, we will have access to a number of core facilities at different sites that are not directly funded by CFAR. A set of policies and procedures has been established to evaluate the performance of each core and to guide decisions in funding reallocation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-07
Application #
2882190
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Plaeger, Susan F
Project Start
1994-04-01
Project End
2001-02-28
Budget Start
1999-03-01
Budget End
2000-02-29
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Heldt, Sven; Prattes, Juergen; Eigl, Susanne et al. (2018) Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect 77:235-241
Garfein, Richard S; Liu, Lin; Cuevas-Mota, Jazmine et al. (2018) Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis 24:1806-1815
Canan, Chelsea E; Chander, Geetanjali; Monroe, Anne K et al. (2018) High-Risk Prescription Opioid Use Among People Living With HIV. J Acquir Immune Defic Syndr 78:283-290
Jenks, Jeffrey Daniel; Hoenigl, Martin (2018) CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. J Lab Precis Med 3:
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Gianella, Sara; Marconi, Vincent C; Berzins, Baiba et al. (2018) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr 79:e112-e114
Innes, Steve; Patel, Kunjal (2018) Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS 13:187-195
Morales, Mario; Rafful, Claudia; Gaines, Tommi L et al. (2018) Factors associated with extrajudicial arrest for syringe possession: results of a department-wide survey of municipal police in Tijuana, Mexico. BMC Int Health Hum Rights 18:36
Rhodes, Tim (2018) The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential. Soc Sci Med 201:71-79

Showing the most recent 10 out of 921 publications